Stay updated with breaking news from Aser Surgery. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Protagonist Therapeutics' rusfertide could have preliminary data next year from its Phase 3 test in polycythemia vera. If the peptide drug wins FDA approval in this rare blood disorder, the partners will share in U.S. commercialization while Takeda is responsible for the drug in the rest of the world.
As key opinion leaders (KOLs), nurses can provide insights on unmet clinical needs, identify gaps in treatment options, and contribute to the development of better and more patient-centric solutions. Here are three core reasons why pharmaceutical companies should tap the power of nurses.
For the first episode of 2024, Senior Reporter Katie Adams discussed some executive hires, promotions and departures that recently took place in the healthcare world, as well as layoffs affecting the industry. We also hear from Kristin Myers, who recently became Northwell Health’s first chief digital officer.
Biogen has returned its Aduhelm rights to Neurimmune, the company that initially developed the antibody Alzheimer’s disease drug. But Biogen isn’t abandoning Alzheimer’s, and its pipeline includes drugs that take other approaches to the neurodegenerative disorder.
We and our collective organizations’ providers have treated 10,000’s of Americans, who suffer from obesity and/or Type 2 diabetes with GLP-1 drugs. And we believe we have important observations to share.